

Evidence and research gaps identified during development of policy guidelines for tuberculosis



Evidence and research gaps identified
during development of policy guidelines for
tuberculosis



Evidence and research gaps identified during development of policy guidelines for tuberculosis
ISBN 978-92-4-004047-2 (electronic version)
ISBN 978-92-4-004048-9 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Evidence and research gaps identified during development of policy guidelines for tuberculosis. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	iv
Acronyms and abbreviations	v
Executive summary	vi
INTRODUCTION	1
Background: Research on TB and a TB-free world are intertwined.	1
Overview of WHO policy development	2
Research questions from TB policy guidelines	2
RESEARCH GAPS	5
Module 1: Prevention	5
1.1 TB preventive treatment	5
1.2 Infection prevention and control	7
Module 2: Screening	8
Module 3: Diagnosis	10
3.1 Initial molecular tests for diagnosis of TB, including drug resistance	10
3.2 Initial biomarker tests for the diagnosis of TB but not drug resistance	11
3.3 Follow-on diagnostic tests for detection of additional drug resistance	12
Module 4: Treatment	12
4.1 Drug-susceptible TB	12
4.2 Drug-resistant TB	14
Module 5: Comorbidities, vulnerable populations and people-centred care	18
5.1 People who inject drugs	18
5.2 Nutritional care and support for patients with TB	19
5.3 Managing TB in children and adolescents	19
ACCELERATING RESEARCH TO ENSURE AN IMPACT	22
CONCLUSIONS	23
REFERENCES	24
Annex: Definitions of research domains used in this document	26

Acknowledgements

The report was written by Nebiat Gebreselassie, with contributions from Dennis Falzon and Matteo Zignol and guidance from Tereza Kasaeva. WHO acknowledges with gratitude the contributions of the members of the various guideline development groups, including members of the WHO Civil Society Task Force, and the TB survivors who contributed to identification of research gaps during development of WHO policy guidance.

Acronyms and abbreviations

GDG	Guideline Development Group
LF-LAM	lateral flow urine lipoarabinomannan
MDR-TB	multidrug-resistant tuberculosis
NAAT	nucleic acid amplification test
TPT	tuberculosis preventive treatment
TB	tuberculosis
TB-LAMP	loop-mediated isothermal amplification for detection of <i>M. tuberculosis</i>
WHO	World Health Organization

Executive summary

Tuberculosis (TB) is a communicable disease that is a major cause of ill health and one of the leading causes of death worldwide. Until the coronavirus pandemic, TB was the leading cause of death from a single infectious agent, ranking above HIV. Although it is a largely preventable, treatable and curable disease, it claims more than one million lives each year and affects millions more, with enormous impacts on families and communities. The End TB Strategy aspires for a 90% reduction in the number of TB deaths and an 80% reduction in TB incidence in 2030 from those in 2015.

Achievement of this goal requires innovative tools and strategies as well as rapid progress towards universal access to health care. It is critical that global policies remain firmly grounded in the best possible evidence in order to optimize the work of national TB programmes and governments. WHO issues recommendations to guide countries in choosing life-saving interventions and effective, efficient, sustainable models of care that have an impact. Experts convened by WHO to provide advice in guideline development also have an important role in identifying important gaps in research and implementation science that would overcome barriers to better care for people affected by TB.

This document summarizes the research gaps compiled by guideline development groups during the latest updates of WHO guidelines on TB (2013–2021). It also provides information about advances in research and development. We trust that this document will guide decision-makers who fund and implement research to better focus their research agendas towards the priorities of TB programmes and affected populations.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23443

